AL
JUNO

Airain Ltd’s Juno Therapeutics, Inc. JUNO Stock Holding History

Airain Ltd’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-6,321
Closed -$278K – 1200
2015
Q4 		$278K Buy
+6,321
New +$313K 0.02% 631

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Airain Ltd's JUNO Position: Q1 2016 in Review

Airain Ltd sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2016, closing a stake of 6,321 shares — an estimated $278K sold.

Airain Ltd first reported a position in JUNO in Q4 2015 and held it in 1 quarter. The position peaked at $278K in Q4 2015. 158 funds tracked by Wall St. Rank hold JUNO as of Q1 2016.

  • Airain Ltd reported no remaining Juno Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • Airain Ltd sold 6,321 Juno Therapeutics, Inc. shares in Q1 2016, an estimated $278K.
  • Airain Ltd first reported a position in Juno Therapeutics, Inc. in Q4 2015 and held it in 1 quarter.
  • Airain Ltd's Juno Therapeutics, Inc. position peaked at $278K in Q4 2015.
  • 158 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2016.

Based on Airain Ltd's 13F filing for Q1 2016, filed 9 May 2016.